Company Profile
Amgen Stock Price, News & Analysis
Company overview
Amgen develops, manufactures, and commercializes therapies across oncology, inflammation, bone health, cardiovascular disease, and rare disease. Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.
Business overview
Amgen develops, manufactures, and commercializes therapies across oncology, inflammation, bone health, cardiovascular disease, and rare disease. Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.
Geographic Base and Sector Classification
Headquartered in Thousand Oaks, California. Classified as Biotechnology and large-cap therapeutics with a global commercial footprint and meaningful U.S. and international revenue exposure.
Business Model Characteristics
A hybrid model where commercial cash flow supports R&D and business development. Launch execution, regulatory events, and portfolio refresh usually matter more than pure clinical-stage binary risk.
Position Within the Biotechnology Landscape
One of the best-known large-cap biotech names. Compared with smaller clinical-stage peers, Amgen usually trades with less single-asset dependence and a steadier catalyst cadence.
Why the stock is moving
AMGN is trading like a steady large-cap biotech name rather than a sharp event-driven move. Its diversified revenue base, recurring approval cycle, and the market's wait for the next earnings or regulatory update keep the stock anchored.
Future catalysts
Over the next three months, the stock is likely to react to earnings, conference commentary, and regulatory follow-through tied to the pipeline or existing labels.
The next earnings call should be the first major checkpoint because it can update revenue trends, margin signals, and management's view on capital allocation and pipeline priorities.
Conference season also matters. Scientific and investor meetings can surface new data points, launch details, and commentary on oncology and cardiometabolic programs before the wider market fully reprices them.
Regulatory milestones and label updates remain the main optionality layer. Any FDA decision or supplemental filing can quickly change the narrative around the newest approved or late-stage assets.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
FDA approves late-stage oncology treatment
Source: amgen.com
- 02
Management commentary keeps pipeline priorities in focus
Source: amgen.com
- 03
Investors watch oncology and cardiometabolic launch cadence
Source: newswire
- 04
Regulatory calendar keeps Amgen in the spotlight
Source: sec.gov
- 05
Pipeline updates reinforce the commercial-stage narrative
Source: conference
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
BMY
Large-cap oncology and immunology peer with a mature commercial base.
GILD
Commercial biotech with antiviral, oncology, and cash flow strength.
REGN
Antibody platform and biologics peer with a strong R&D engine.
VRTX
High-quality biotech with durable launch execution and pipeline optionality.
INCY
Oncology and immunology exposure with catalyst-driven trading behavior.